1. Home
  2. HTCR vs ONCO Comparison

HTCR vs ONCO Comparison

Compare HTCR & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartcore Enterprises Inc.

HTCR

Heartcore Enterprises Inc.

HOLD

Current Price

$2.00

Market Cap

3.5M

Sector

Technology

ML Signal

HOLD

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.64

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTCR
ONCO
Founded
2009
2018
Country
Japan
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
3.0M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
HTCR
ONCO
Price
$2.00
$0.64
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.3K
381.5K
Earning Date
05-14-2026
06-11-2026
Dividend Yield
87.84%
N/A
EPS Growth
414.29
22.80
EPS
N/A
N/A
Revenue
$30,407,229.00
$815,371.00
Revenue This Year
$123.26
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.19
N/A
52 Week Low
$0.15
$0.09
52 Week High
$3.97
$6.73

Technical Indicators

Market Signals
Indicator
HTCR
ONCO
Relative Strength Index (RSI) 39.12 43.38
Support Level $0.23 $0.61
Resistance Level $3.77 $1.02
Average True Range (ATR) 0.19 0.09
MACD -0.01 -0.00
Stochastic Oscillator 29.12 15.73

Price Performance

Historical Comparison
HTCR
ONCO

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: